ZITANEO-M-500SR Tablets & ZITANEO-50

Improved Control with Better Compliance

 

COMPOSITION.

Sitagliptin 50mg + Metformin Hcl 500mg (SR) Tablets

INDICATION

  1. Diabetes type-2
  2. Hyperglycemia
  3. Insulin resistance.
  4. Gestational/Pre-gestational diabetes
  5.  Diabetic neuropathy
  6. Insulin Adjunctive therapy

ZITANEO-M-500SR Tablets

Sitagliptin
  • Potent and highly selective hypoglycemic agent, used in the management of adults with type 2 diabetes.
  • Clinical trials have demonstrated the efficacy of sitagliptin in terms of improving glycaemic control in patients with type 2 diabetes, including its use in combination with metformin.
  • Demonstrates glycaemic efficacy in a broad spectrum of patients with Type 2 diabetes, including obese, elderly, and renal impaired patients and those with cardiovascular disease (CVD).
  •  It has a convenient once-daily oral regimen, low potential for pharmacokinetic drug-drug interactions, good efficacy, and safety profile. (Drugs 2017 Feb 770) 209-224)

Metformin (SR)

  • The first-line anti-hyperglycemic agent shows excellent action in the treatment of type-2 Diabetes Mellitus.
  • Is also safe and effective in the treatment of gestational diabetes and pregestational diabetes.
  • Prevents diabetic neuropathy in patients and improves insulin resistance as an adjunct
  • Shows exceptional drug absorption and bioavailability without any adverse effects.
  • O Reduces glucose production and intestinal absorption of glucose by increasing peripheral glucose uptake